87 research outputs found

    An Analysis of Once-per-revolution Oscillating Aerodynamic Thrust Loads on Single-Rotation Propellers on Tractor Airplanes at Zero Yaw

    Get PDF
    A simplified procedure is shown for calculating the once-per-revolution oscillating aerodynamic thrust loads on propellers of tractor airplanes at zero yaw. The only flow field information required for the application of the procedure is a knowledge of the upflow angles at the horizontal center line of the propeller disk. Methods are presented whereby these angles may be computed without recourse to experimental survey of the flow field. The loads computed by the simplified procedure are compared with those computed by a more rigorous method and the procedure is applied to several airplane configurations which are believed typical of current designs. The results are generally satisfactory

    Full-Scale Wind-Tunnel Tests of Blowing Boundary-Layer Control Applied to a Helicopter Rotor

    Get PDF
    A full-scale wind-tunnel test was conducted of two boundary-layer-control applications to a 44-foot diameter helicopter rotor. Blowing from a nozzle near the leading edge of the blades delayed retreating blade stall. Results also indicated that delay of retreating blade stall could be obtained by cyclic blowing with a lower flow rate than that required for continuous blowing. It was found that blowing applied through a nozzle at mid-chord had no effect on retreating blade stall

    Tests of Full-Scale Helicopter Rotors at High Advancing Tip Mach Numbers and Advance Ratios

    Get PDF
    As a continuation of the studies of reference 1, three full-scale helicopter rotors have been tested in the Ames Research Center 40- by SO-foot wind tunnel. All three of them were two-bladed, teetering rotors. One of the rotors incorporated the NACA 0012 airfoil section over the entire length of the blade. This rotor was tested at advance ratios up to 1.05. Both of the other rotors were tapered in thickness and incorporated leading-edge camber over the outer 20 percent of the blade radius. The larger of these rotors was tested at advancing tip Mach numbers up to 1.02. Data were obtained for a wide range of lift and propulsive force, and are presented without discussion

    Examining pathways between genetic liability for schizophrenia and patterns of tobacco and cannabis use in adolescence

    Get PDF
    Background It is not clear to what extent associations between schizophrenia, cannabis use and cigarette use are due to a shared genetic etiology. We, therefore, examined whether schizophrenia genetic risk associates with longitudinal patterns of cigarette and cannabis use in adolescence and mediating pathways for any association to inform potential reduction strategies. Methods Associations between schizophrenia polygenic scores and longitudinal latent classes of cigarette and cannabis use from ages 14 to 19 years were investigated in up to 3925 individuals in the Avon Longitudinal Study of Parents and Children. Mediation models were estimated to assess the potential mediating effects of a range of cognitive, emotional, and behavioral phenotypes. Results The schizophrenia polygenic score, based on single nucleotide polymorphisms meeting a training-set p threshold of 0.05, was associated with late-onset cannabis use (OR = 1.23; 95% CI = 1.08,1.41), but not with cigarette or early-onset cannabis use classes. This association was not mediated through lower IQ, victimization, emotional difficulties, antisocial behavior, impulsivity, or poorer social relationships during childhood. Sensitivity analyses adjusting for genetic liability to cannabis or cigarette use, using polygenic scores excluding the CHRNA5-A3-B4 gene cluster, or basing scores on a 0.5 training-set p threshold, provided results consistent with our main analyses. Conclusions Our study provides evidence that genetic risk for schizophrenia is associated with patterns of cannabis use during adolescence. Investigation of pathways other than the cognitive, emotional, and behavioral phenotypes examined here is required to identify modifiable targets to reduce the public health burden of cannabis use in the population

    Examining pathways between genetic liability for schizophrenia and patterns of tobacco and cannabis use in adolescence

    Get PDF
    Background It is not clear to what extent associations between schizophrenia, cannabis use and cigarette use are due to a shared genetic etiology. We, therefore, examined whether schizophrenia genetic risk associates with longitudinal patterns of cigarette and cannabis use in adolescence and mediating pathways for any association to inform potential reduction strategies. Methods Associations between schizophrenia polygenic scores and longitudinal latent classes of cigarette and cannabis use from ages 14 to 19 years were investigated in up to 3925 individuals in the Avon Longitudinal Study of Parents and Children. Mediation models were estimated to assess the potential mediating effects of a range of cognitive, emotional, and behavioral phenotypes. Results The schizophrenia polygenic score, based on single nucleotide polymorphisms meeting a training-set p threshold of 0.05, was associated with late-onset cannabis use (OR = 1.23; 95% CI = 1.08,1.41), but not with cigarette or early-onset cannabis use classes. This association was not mediated through lower IQ, victimization, emotional difficulties, antisocial behavior, impulsivity, or poorer social relationships during childhood. Sensitivity analyses adjusting for genetic liability to cannabis or cigarette use, using polygenic scores excluding the CHRNA5-A3-B4 gene cluster, or basing scores on a 0.5 training-set p threshold, provided results consistent with our main analyses. Conclusions Our study provides evidence that genetic risk for schizophrenia is associated with patterns of cannabis use during adolescence. Investigation of pathways other than the cognitive, emotional, and behavioral phenotypes examined here is required to identify modifiable targets to reduce the public health burden of cannabis use in the population

    A pragmatic, phase III, multisite, double-blind, placebo-controlled, parallel-arm, dose increment randomised trial of regular, low-dose extended-release morphine for chronic breathlessness: Breathlessness, Exertion And Morphine Sulfate (BEAMS) study proto

    Get PDF
    © Article author(s). Introduction Chronic breathlessness is highly prevalent and distressing to patients and families. No medication is registered for its symptomatic reduction. The strongest evidence is for regular, low-dose, extended-release (ER) oral morphine. A recent large phase III study suggests the subgroup most likely to benefit have chronic obstructive pulmonary disease (COPD) and modified Medical Research Council breathlessness scores of 3 or 4. This protocol is for an adequately powered, parallel-Arm, placebo-controlled, multisite, factorial, block-randomised study evaluating regular ER morphine for chronic breathlessness in people with COPD. Methods and analysis The primary question is what effect regular ER morphine has on worst breathlessness, measured daily on a 0-10 numerical rating scale. Uniquely, the coprimary outcome will use a FitBit to measure habitual physical activity. Secondary questions include safety and, whether upward titration after initial benefit delivers greater net symptom reduction. Substudies include longitudinal driving simulation, sleep, caregiver, health economic and pharmacogenetic studies. Seventeen centres will recruit 171 participants from respiratory and palliative care. The study has five phases including three randomisation phases to increasing doses of ER morphine. All participants will receive placebo or active laxatives as appropriate. Appropriate statistical analysis of primary and secondary outcomes will be used. Ethics and dissemination Ethics approval has been obtained. Results of the study will be submitted for publication in peer-reviewed journals, findings presented at relevant conferences and potentially used to inform registration of ER morphine for chronic breathlessness. Trial registration number NCT02720822; Pre-results
    corecore